In a formal appeal, the Pakistan Pharmaceutical Manufacturers Association (PPMA) urged authorities to either lift the ban or, at the very least, establish clear Standard Operating Procedures (SOPs) to regulate hospital visits by MRs. The association emphasized that recent measures have placed undue strain on the healthcare ecosystem and threatened livelihoods.
The issue gained attention after three medical reps were arrested for allegedly violating hospital entry rules. They were later released on bail. The arrests sparked concern among pharmaceutical firms, which contend that MRs play a critical role in keeping doctors informed about medicines and their possible side effects a practice recognized worldwide as a professional responsibility rather than mere commercial promotion.
PPMA’s former chairman, Tauqeer-ul-Haq, commented, ‘Our hope is to meet with the Health Minister in the coming days to clarify these matters. Medical reps are not criminals; they carry out a respected, professional role that ultimately benefits patients.’ He suggested that if the government has concerns about hospital visits, the solution should not be arrests but structured guidelines detailing visit timings and duration.
He further added, ‘Medical reps can be regulated in consultation with pharmaceutical companies. A formal framework is far more effective than punitive measures.’ Tauqeer ul Haq also highlighted that pharmaceutical firms supply medicines to public hospitals at cost effective rates, supporting the healthcare system, and provide employment to thousands of young professionals who also contribute as taxpayers.
PPMA Senior Vice Chairman, Kamran Nasir, noted that the association is reviewing the situation carefully and aims to respond in a balanced manner, including dialogue with the Punjab government to prevent any future conflicts that could hurt all stakeholders.
Meanwhile, the Punjab Health Department maintains a strict ban on private pharmaceutical reps entering government hospitals. Hospital superintendents have been instructed to take legal and disciplinary action against violators, including doctors, to prevent undue influence on prescriptions and avoid conflicts of interest. The department asserts that the ban is intended to protect patients from commercial interference.
As tensions persist, the pharmaceutical industry remains steadfast in advocating for a regulated, transparent system that protects both professional roles and patient welfare, urging a middle path that balances oversight with opportunity.
